15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Mirum Pharmaceuticals Inc, 15 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $95.00 to $175.00, a moderate spread. The average target of $137.62 sits 20% above the current $114.24. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.69 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Moderate Buy
Strong Buy17%
Buy1493%
Hold00%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Mirum Pharmaceuticals Inc.
As of Jul, 15 of 15 firms rate MIRM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MIRM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-1.06 – $-0.40 · 5 analysts · -1472% YoY
Next period, 5 analysts expect Mirum Pharmaceuticals Inc to earn $-0.69 a share (range $-1.06 – $-0.40), versus $0.05 a year earlier. Full-year consensus is $-14.24, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$172.0M
Range $168.9M – $173.5M · 5 analysts · +29% YoY
Revenue is expected to reach $172.0M (range $168.9M – $173.5M), +29.3% year-over-year. Full-year consensus is $675.3M, rising to $815.1M next year.
Top analysts covering Mirum Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIRM.
#1
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$132.00+15.5% to target
Overall win rate
44%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Buy
$125.00+9.4% to target
Overall win rate
52%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$145.00+26.9% to target
Overall win rate
43%
+ Follow
#4
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$95.00-16.8% to target
Overall win rate
38%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$175.00+53.2% to target
Overall win rate
37%
+ Follow
MIRM stock forecast FAQ
What is MIRM's average 12-month price target?+
The 13 analysts with a live target average $137.62 for Mirum Pharmaceuticals Inc over the next 12 months, ranging from a $175.00 high to a $95.00 low.
Is MIRM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 15 analyst ratings, 15 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MIRM?+
The Street-high target is $175.00 (HC Wainwright & Co.), and the Street-low is $95.00 (Cantor Fitzgerald). The average of all 13 active targets is $137.62.
How many Wall Street analysts cover MIRM?+
15 analysts have an active rating on Mirum Pharmaceuticals Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering MIRM?+
Among analysts who currently cover MIRM, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #38). Their current call is Buy with a $132.00 target.
What is Mirum Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-1.06 – $-0.40) across 5 analysts. Full-year EPS is projected at $-14.24, rising to $-0.19 the following year.
How much revenue is Mirum Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $172.0M (range $168.9M – $173.5M). Full-year revenue is projected at $675.3M, growing to $815.1M next year.
Have analysts been upgrading or downgrading MIRM lately?+
As of Jul, 15 of 15 firms rate MIRM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIRM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
